We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Zebra Fish Model Yields Clues to Neuroblastoma Growth

By LabMedica International staff writers
Posted on 15 Sep 2017
A genome-wide association study (GWAS) conducted in a zebra fish model system identified LMO1, which encodes a LIM-domain-only transcriptional cofactor, as a neuroblastoma susceptibility gene that functions as an oncogene in high-risk neuroblastoma.

Neuroblastoma is a cancer that most commonly affects children age five years or younger, though it may rarely occur in older children. More...
The cancer develops from immature nerve cells found in several areas of the body but most commonly arises in and around the adrenal glands, which have similar origins to nerve cells.

Investigators at the Mayo Clinic (Rochester, MN, USA) studied the mechanism used by neuroblastoma to grow and spread. They reported in the August 31, 2017, online edition of the journal Cancer Cell that genetic analyses using zebra fish demonstrated that LMO1 cooperated with the MYCN gene to accelerate tumor onset and progression.

In zebra fish expressing both MYCN and LMO1, the investigators observed tumor development in 80% of the offspring by 24 weeks of age. In offspring expressing only the MYCN gene, tumors developed in only 20 to 30% during the same time period.

The transgenic expression of LMO1 promoted neuroblastoma dissemination and distant metastasis, which was linked to cell invasion and migration, and elevated expression levels of genes affecting tumor cell-extracellular matrix interaction.

"This is the first evidence in an animal model that high levels of LMO1 expression promote metastasis of MYCN-induced neuroblastoma," said first author Dr. Shizhen Zhu, a biomedical researcher at the Mayo Clinic. "Increased expression of the LMO1 gene is associated with aggressive, high-risk neuroblastomas. Our genetic analyses using zebra fish demonstrates for the first time that LMO1 cooperates with the MYCN gene to accelerate tumor onset and increase tumor penetrance. Our zebra fish model of neuroblastoma with transgenic expression of LMO1 and MYCN should provide a valuable platform for evaluating the effects of drugs to prevent or inhibit neuroblastoma metastasis going forward."

Related Links:
Mayo Clinic


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HPV Test
Allplex HPV28 Detection
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.